MUSTANG BIO, INC. Stock Split Ratio
MUSTANG BIO, INC. (MBIO) reported Stock Split Ratio of 2.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2026-08-05
- MUSTANG BIO, INC. stockholders' equity note, stock split, conversion ratio for the quarter ending 2025-03-31 was 2.00%.
- MUSTANG BIO, INC. stockholders' equity note, stock split, conversion ratio for fiscal 2025 was 2.00%, a 0.00% change from fiscal 2024.
- MUSTANG BIO, INC. stockholders' equity note, stock split, conversion ratio for fiscal 2024 was 2.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 3 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 6 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 9 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | 2.00% 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | 2.00% 10-Q · filed 2025-11-07 | ||||
| 2025-06-30 | 2.00% 10-Q · filed 2026-08-05 | ||||
| 2025-03-31 | 2.00% 10-Q · filed 2026-05-05 | ||||
| 2025-01-15 | 2.00% 10-K · filed 2026-03-19 | ||||
| 2024-12-31 | 2.00% 10-K · filed 2026-03-19 | ||||
| 2023-09-30 | 1500.00% 10-Q · filed 2024-11-08 | ||||
| 2023-03-15 | 6.67% 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |